Format

Send to

Choose Destination
Immunol Today. 1996 Mar;17(3):106-8.

FK506 in the treatment of inflammatory skin disease: promises and perspectives.

Author information

1
Department of Dermatology, Heinrich-Heine-University, Dusseldorf, Germany. MICHELG@RZ.UNI-DUSSELDORF.DE

Abstract

The immunosuppressive macrolide drug FK506 is currently gaining increasing importance in dermatopharmacology. Here, Gunter Michel and colleagues summarize the current state of research into the molecular mechanisms responsible for the functional modulation of cell types other than T cells, particularly epidermal cells, by this drug.

PMID:
8820265
DOI:
10.1016/0167-5699(96)80599-8
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center